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Introduction
Systemic juvenile idiopathic arthritis (sJIA) accounts for
10-20% of all patients with JIA. The clinical features
include fever, evanescent rash, arthralgia and arthritis,
myalgia, lymphadenopathy, hepatomegaly, splenomegaly
and serositis. Interleukin 1 (IL-1) has been shown to be a
major mediator of the inflammatory cascade that underlies
sJIA (1). Treatment with anakinra, IL-1 receptor antago-
nist has been reported to be effective in a subset of
patients with sJIA (2)
Objectives
To assess anakinra as a therapy for sJIA in a single-center
series.
Methods
We reviewed twenty-one consecutive patients with sJIA
treated with anakinra for at least 6 months in our institu-
tion. The diagnosis of sJIA was established according to
the International League of Associations for Rheumatology
(ILAR) criteria. We analyzed the effect of Anakinra on
fever, rash, number of actives joints, erythrocyte sedimenta-
tion rate (ESR), C-reactive protein (CRP), white blood cell
count, platelet count and ferritin levels. Clinically inactive
disease was defined according to Wallace criteria. Clinical
and laboratory data were obtained using a standard data
collection form end resulting data were analyzed using
Fisher exact test.
Results
At the beginning of treatment mean age (range) was 8.57
(2.15-16.63) years; 19 of 21 patients had fever and median
number of active joints was 3 (1-15). After 6 months of
treatment 11 patients (52.3%) met the criteria for inactive
disease. Among 21 patients 7 (33%) received anakinra in
monotherapy and 14 (66.6%) received anakinra with
glucocorticoids. There were no statistically significant dif-
ferences between the two groups for demographic, clinical
and laboratory features. Five of 7 pts (71.4%) treated with
anakinra alone and 6 of 14 pts (42.9%) treated with
anakinra and glucocorticoids met criteria for inactive
disease at 6 months (p= 0.361). Among the 21 patients,
10 (47.6%) received anakinra in the first 6 months of
disease. There were no statistically significant differences
for demographic, clinical and laboratory features among
patients who started anakinra in the first 6 months of
disease and those that started it after 6 months from onset
of disease. At 6 months after initiation of anakinra treat-
ment 8 of 10 patients (80%) who started anakinra during
the first 6 months of disease and 4 out of 11 (36.4%) who
started anakinra after 6 months of disease reached clinical
inactive disease (p=0.08).
Conclusion
In agreement with several observations, anakinra is effec-
tive in a significant proportion of patients with sJIA. Our
observation, albeit on a small number, show that associa-
tion with glucocorticoids does not significantly affect
outcome at 6 months and suggest, on the other hand, that
earlier treatment may be associated with a better outcome.
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